Table 1. Baseline characteristics according to Epstein-Barr virus results.
| Total patientsn = 110 (%) | EBV-DNA positiven = 47 (%) | EBV-DNA negativen = 63 (%) | P value | |
|---|---|---|---|---|
| Age | 0.436 | |||
| > 60 years | 63 (57.3) | 30 (63.8) | 35 (55.6) | |
| ≤ 60 years | 47 (42.7) | 17 (36.2) | 28 (44.4) | |
| Sex | 0.171 | |||
| Male | 65 (59.1) | 24 (51.1) | 41 (65.1) | |
| Female | 45 (40.9) | 23 (48.9) | 22 (34.9) | |
| Performance status | 0.198 | |||
| ECOG 0-1 | 80 (72.7) | 31 (34.0) | 49 (77.8) | |
| ECOG ≥ 2 | 30 (27.3) | 16 (66.0) | 14 (22.2) | |
| Lymphoma subtype | 0.775 | |||
| PTCL, NOS | 73 (66.4) | 32 (68.1) | 41 (65.1) | |
| AITL | 22 (20.0) | 10 (21.3) | 12 (19.0) | |
| Others | 15 (13.6) | 5 (10.6) | 10 (15.9) | |
| B symptoms | 0.324 | |||
| Negative | 56 (53.8) | 22 (47.8) | 34 (58.6) | |
| Positive | 48 (46.2) | 24 (52.2) | 24 (41.4) | |
| Stage | 0.007 | |||
| Stage I/II | 13 (11.8) | 1 (2.0) | 12 (19.0) | |
| Stage III/IV | 97 (88.2) | 46 (98.0) | 51 (81.0) | |
| Extranodal sites | 0.999 | |||
| 0-1 | 73 (66.4) | 31 (66.0) | 42 (66.7) | |
| ≥ 2 | 37 (33.6) | 16 (34.0) | 21 (33.3) | |
| Lactic dehydrogenase | 0.004 | |||
| Normal | 35 (31.8) | 8 (17.0) | 27 (42.9) | |
| Elevated | 75 (68.2) | 39 (83.0) | 36 (57.1) | |
| Bone marrow involvement | 0.234 | |||
| Negative | 56 (53.3) | 20 (45.5) | 36 (59.0) | |
| Positive | 49 (46.7) | 24 (54.5) | 25 (41.0) | |
| IPI at diagnosis | 0.114 | |||
| Low/Low-intermediate | 43 (39.1) | 14 (29.8) | 29 (46.0) | |
| High-intermediate/High | 67 (60.9) | 33 (70.2) | 34 (54.0) | |
| PIT at diagnosis | 0.207 | |||
| Group 1/2 | 34 (32.4) | 11 (25.0) | 23 (37.7) | |
| Group 3/4 | 71 (67.6) | 35 (75.0) | 38 (62.3) | |
| Response | 0.247 | |||
| CR/PR | 58 (65.2) | 18 (56.3) | 40 (70.2) | |
| SD/PD | 31 (34.8) | 14 (43.8) | 17 (29.8) | |
| ALC | 0.557 | |||
| ≥ 1,000 | 66 (60.0) | 30 (63.8) | 36 (57.1) | |
| < 1,000 | 44 (40.0) | 17 (38.2) | 27 (42.9) | |
| Albumin | 0.004 | |||
| ≥ 3.5 | 58 (52.7) | 17 (36.2) | 41 (65.1) | |
| < 3.5 | 52 (47.3) | 30 (63.8) | 22 (34.9) | |
| Ferritin | 0.796 | |||
| > 1,000 | 18 (17.5) | 9 (19.1) | 9 (16.1) | |
| ≤ 1,000 | 85 (82.5) | 38 (80.9) | 47 (83.9) | |
| EBER-ISH | 0.766 | |||
| Negative | 27 (58.7) | 11 (55.0) | 16 (61.5) | |
| Positive | 19 (41.3) | 9 (45.0) | 10 (38.5) |
Abbreviations: EBV, Epstein-Barr virus; ECOG, Eastern Cooperative Oncology Group; PTCL, NOS, peripheral T-cell lymphoma, not otherwise specified; AITL, Angioimmunoblastic T-cell lymphoma; IPI, International Prognostic Index; PIT Prognostic Index for PTCL-u; CR, Complete response; PR, Partial response; SD, Stable disease; PD, progressive disease; ALC, Absolute lymphocyte count; EBER-ISH, EBV-encoded small RNAs-in situ hybridization.